Homoeopathic treatment of respiratory sequelae of post- covid cases: an open label prospective study

Homoeopathic treatment of respiratory sequelae of post- covid cases: an open label prospective interventional pilot study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032225

Enrollment

Registered

2021-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Homoeopathic medications based upon symptom analysis (Dose and timing will vary from patient to patient): Homoeopathic medications based upon symptom analysis (Dose and timing will vary

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years 2. Previously positive COVID cases (ICD code: U07.1) 3. Patient who tested to be COVID-19 negative, 4 weeks after discharge from COVID Care Centre. 4. Patient presenting with any of the respiratory symptoms such as - shortness of breath, cough, expectoration, chest pain and other respiratory complaints (ICD code: B97.29) 5. HRCT confirmed cases of COVID Lung Damage like ground glass opacities and fibrosis 6. PFT with features of restriction evidenced by FVC 7. Willing to give consent in writing

Exclusion criteria

Exclusion criteria: 1. Patients who are tested to be COVID-19 positive, at the time of enrollment in the study. 2. Patient with previous history of COPD, Asthma, Bronchiectesis and Chronic Cardiac ailments 3. Pregnant and lactating women 4. Patients who are not willing to volunteer for the study. 5. Patients developing serious complications, Immuno-compromisedpatients 6. Idiosyncratic reactions, severe medicinal aggravation and requiring ventilator support or emergency surgical intervention.

Design outcomes

Primary

Measure	Time frame
To study the role of homoeopathic treatment in Respiratory sequelae of Post COVID cases.Timepoint: at 3 months	—

Secondary

Measure	Time frame
To study the time of recoveryTimepoint: at 3 months	—

Countries

India

Contacts

Public ContactAnant Mohan

All India Institute of Medical Sciences, New Delhi

anantmohan@yahoo.com

Outcome results